RESEARCH TRIANGLE PARK, NCZofran (ondansetron HCl), Glaxo
Wellcomes 5HT3 antagonist antiemetic, has received FDA approval
for a new indication and a new tablet strength
Zofran is now indicated for the prevention of nausea and vomiting
associated with single-day highly emetogenic cancer chemotherapy in
adults, ie, chemotherapy in which the likelihood of nausea and
vomiting is greater than 90% without prior antiemetic treatment.
The Zofran dose for highly emetogenic chemotherapy is 24 mg once
daily, which can be given via the newly approved 24-mg tablet or
three 8-mg tablets.
Zofran is also indicated for the prevention of nausea and vomiting
associated with moderately emetogenic chemotherapy in adults and
children, the prevention of nausea and vomiting associated with
radiotherapy in adults, and the prevention of postoperative nausea
and vomiting in adults.